126489-69-8 Usage
Type of compound
Aromatic amine derivative
Structure
A propanediol molecule with an amino group attached to the aromatic ring
Applications
a. Synthesis of pharmaceuticals and organic compounds
b. Production of polyesters, polyurethanes, and epoxy resins
c. Reagent in organic synthesis
d. Intermediate in the production of dyes and pigments
Potential uses
a. Antioxidant
b. Anti-inflammatory agent
c. Pharmaceutical and nutraceutical industries
Molecular weight
166.22 g/mol
Appearance
Colorless to pale yellow liquid or solid
Solubility
Soluble in water, ethanol, and other polar solvents
Stability
Stable under normal temperature and pressure conditions
Reactivity
Reacts with oxidizing agents, acids, and bases
Hazards
May be harmful if swallowed, inhaled, or absorbed through the skin
Safety measures
Use appropriate personal protective equipment (PPE) and handle in a well-ventilated area
Storage
Store in a cool, dry, and well-ventilated area, away from incompatible substances and sources of ignition
Disposal
Dispose of in accordance with local, national, and international regulations for hazardous materials
Environmental impact
Potentially harmful to aquatic life and should be handled with care to prevent environmental contamination
Regulatory status
May be subject to specific regulations and restrictions depending on the region and intended use.
Check Digit Verification of cas no
The CAS Registry Mumber 126489-69-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,4,8 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 126489-69:
(8*1)+(7*2)+(6*6)+(5*4)+(4*8)+(3*9)+(2*6)+(1*9)=158
158 % 10 = 8
So 126489-69-8 is a valid CAS Registry Number.
126489-69-8Relevant articles and documents
Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
Wilson, Kenneth J.,Illig, Carl R.,Chen, Jinsheng,Wall, Mark J.,Ballentine, Shelley K.,Desjarlais, Renee L.,Chen, Yanmin,Schubert, Carsten,Donatelli, Robert,Petrounia, Ioanna,Crysler, Carl S.,Molloy, Christopher J.,Chaikin, Margery A.,Manthey, Carl L.,Player, Mark R.,Tomczuk, Bruce E.,Meegalla, Sanath K.
scheme or table, p. 3925 - 3929 (2010/09/03)
During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead ary
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design
Chand, Pooran,Babu, Yarlagadda S.,Bantia, Shanta,Chu, Naiming,Cole, L. Brent,Kotian, Pravin L.,Laver, W. Graeme,Montgomery, John A.,Pathak, Ved P.,Petty, Sandra L.,Shrout, David P.,Walsh, David A.,Walsh, Gerald M.
, p. 4030 - 4052 (2007/10/03)
A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4- (acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10-6 M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.
